Relapsed Non Hodgkin Lymphoma Recruiting Phase 1 / 2 Trials for Rituximab (DB00073)

IndicationStatusPhase
DBCOND0062858 (Relapsed Non Hodgkin Lymphoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03892421Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin LymphomaTreatment
NCT03778619MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell OriginTreatment